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S U P P L E M E N T A R T I C L E
Biomedical Prevention: State of the Science
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Carolina at Chapel Hill
Preexposure prophylaxis (PrEP) and treatment as prevention (TasP) involve the use of antiretroviral (ARV)
drugs by human immunodeﬁciency virus (HIV)-negative and -positive individuals to reduce HIV acquisition
and transmission, respectively. Clinical science has delivered a consistently high effect size for TasP and a range
from 0%–73% reduction in incidence across placebo-controlled PrEP trials. However, the quality of evidence for
PrEP compares favorably with evidence for postexposure prophylaxis (PEP). It is clear from treatment programs
and PrEP trials that daily adherence presents challenges to a large proportion of the population. Although there
are factors associated with inconsistent use (ie, younger age), they do not assist clinicians at the point of care.
There are additional provider concerns about PrEP (covering cost of drug and delivery, undermining condom
promotion, and facilitating resistant strains) that have delayed widespread acceptance. These issues need to be
addressed in order to realize the full public health potential of antiretrovirals.
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The ﬁrst demonstration that human immunodeﬁciency
virus (HIV) could be prevented with a biomedical inter-
vention was the dramatic reduction of transmission
from mother to child in 1994 with use of a single
drug, zidovudine, in a complex regimen that was not
practical to implement in all settings [1]. Randomized
placebo-controlled trials of more practical regimens
were undertaken, eliciting controversy in the literature
but providing the necessary evidence for the World
Health Organization (WHO) to modify guidelines
and incorporate a range of options. More potent regi-
mens have followed; however, in 2012 an estimated
260 000 babies in low- and middle-income countries
were infected with HIV from their mother [2].
Scientiﬁc endeavors have delivered robust evidence
for the biological efﬁcacy of preexposure prophylaxis
(PrEP) [3] and treatment as prevention (TasP) [4].
There is cautious optimism for tenofovir 1% vaginal
microbicide [5] and a glimmer of hope for combination
vaccine regimens, with signiﬁcant protection demon-
strated in 1 trial (RV144) [6]. In contrast, the evidence
base for postexposure prophylaxis (PEP) following sex-
ual exposure is weak, with supporting preclinical and
cohort data only (mainly occupational) [7].
This review, which is based on the 2013 International
Association of Providers of AIDS Care (IAPAC) summit
“Controlling the HIV Epidemic With Antiretrovirals,”
held in London, focuses exclusively on the use of antire-
troviral (ARV) drugs to prevent onward transmission to
sexual partners (TasP), as postexposure prophylaxis after
sex (PEPSE), and before the event (PrEP, microbicides).
We identify the challenges in translating the science for
prescribers and users, and the difﬁculty that the lack of
precision around the estimates of effect presents for pro-
gressing drugs that are currently in early development.
EVIDENCE FOR EFFICACY
Academic groups working independently of each other
have collected the evidence for each biomedical interven-
tion. Whether by serendipity or Gilead Sciences’ fore-
sight in making tenofovir and Truvada accessible, there
is a comprehensive portfolio for these ARV drugs
when used as oral and topical PrEP. This includes
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preclinical challenge experiments [8, 9], pharmacokinetic data
with and without a pharmacodynamic endpoint [10–14], and
randomized placebo-controlled clinical trial data in a range of di-
verse populations [5, 15–20].
THE CHALLENGE OF NO TRIAL:
POSTEXPOSURE PROPHYLAXIS
The evidence base for PEPSE is at the bottom of the Grading of
Recommendations Assessment, Development, and Evaluation
(GRADE) system for rating evidence [21], relying heavily on
preclinical data and cohort data (mainly following occupational
injury) [7]. Despite this, it is widely available in all countries
using ARV drugs licensed for the treatment of HIV. The
72-hour limit for starting PEPSE after exposure is derived
from preclinical data [22, 23] but endorsed by clinical data col-
lected after known exposure [24–26]. Earlier is clearly better.
Therefore, it is not appropriate to assess time to start in a
randomized trial; however, surely it is time to assess shorter reg-
imens given the evidence that HIV is disseminated 5–10 days
after exposure [27].
THE ADVANTAGE OF THE SINGLE TRIAL
AND A SURROGATE MARKER
When HIV Prevention Trials Network (HPTN) 052 random-
ized the ﬁrst participant to early or deferred antiretroviral ther-
apy (ART), there was already a body of evidence that supported
negligible risk of onward transmission from positive individuals
with undetectable virus in the plasma [28, 29]. The evidence
available in 2008 was sufﬁcient to lead the Swiss to issue a state-
ment to this effect [30]; this statement led to considerable con-
troversy when presented at the XVII International AIDS Society
Conference in Mexico City [31]. The controversy created uncer-
tainty, and the majority of healthcare workers felt uncomfort-
able advising patients they were not infectious and deemed it
necessary to mention the caveats to them (eg, unable to extrap-
olate from cohort populations due to differing sexual practices,
virus in the genital compartment if not the plasma, the possibil-
ity that other sexually transmitted infections [STIs] are present
to increase susceptibility or viral shedding). HPTN 052 changed
that by providing a single, very high estimate of effect, that is,
96%, together with the explanation that the single infection
that was transmitted most likely occurred before the positive
individual became undetectable [28]. The caveats have not en-
tirely disappeared, but the message for the individual consider-
ing this option is clear, with the WHO strongly recommending
initiation of treatment for the HIV-infected partner in a dis-
cordant sexual relationship, regardless of CD4 count or WHO
stage of disease, so as to prevent onward transmission [32]. This
recommendation is for serodiscordant couples of any
orientation, although data for men who have sex with men
(MSM) are lacking [33].
The public health beneﬁt of TasP is not so clear and is being
speciﬁcally addressed in 4 randomized trials being conducted in
heterosexual populations in countries in sub-Saharan Africa
with generalized epidemics [34, 35]. However, the incidence of
HIV in gay and other MSM is rising in several countries that
have robustly implemented ART programs, leading some ex-
perts to conclude that TasP alone will not eradicate HIV in
these focused epidemics [33, 36, 37].
THE PROS AND CONS OF MULTIPLE, WIDE-
RANGING ESTIMATES FOR PrEP
Statistically signiﬁcant reduction in HIV incidence is a clear
endpoint, and the demonstration of this in diverse populations
leaves no room for doubt that daily oral Truvada has biological
efﬁcacy. However, there is uncertainty about the size of the
effect, as the range of beneﬁts observed in clinical trials goes from
no beneﬁt to 73% reduction in HIV incidence compared with
placebo. This uncertainty makes it difﬁcult to articulate a
simple, clear message for prescribers and users of PrEP regard-
ing how much protection daily Truvada will provide, although
it is clear that it can only work if it is taken. Even though the
differences between the trials can be explained by the differenc-
es in the proportion who were taking the drug [38], there
are distracting caveats in the literature that include lower
levels of drug in the female genital tract [39], the vulnerability
of rectal epithelial cells [40, 41], and the presence of facilitating
STIs [42].
The uncertainty around the effect size for Truvada, the only
licensed drug for PrEP, also presents a challenge for those wish-
ing to demonstrate the effectiveness of alternative drugs for
PrEP. Where biological efﬁcacy is uncertain, the most robust
control remains a placebo [43].This is why the tenofovir vaginal
microbicide trial FACTS001, the “before and after sex” Truvada
PrEP trial iPerGay, and the 2 dapivirine vaginal ring studies
(ASPIRE and the Ring) are using placebo controls [44]. In the
absence of a validated surrogate marker for efﬁcacy, it is difﬁcult
to see a future for oral PrEP that does not include large nonin-
feriority trials with extensive pharmacokinetic sampling in
order to determine the proportion taking the drug in each
group so that the analyses can be adjusted for differences in ad-
herence. What level of efﬁcacy should these designs assume for
the daily Truvada control? Should it be 90%, as suggested by the
2 nested case-control studies in iPrEx and Partners? Or some-
where between the 44% seen in iPrEx and the 73% seen in Part-
ners? The choice is likely to be driven by practicalities such as
the sample size that can be achieved, which can be a recipe for
underpowered trials. Interpretation of the results of such trials is
guaranteed to be challenging [45].
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ADHERENCE BEHAVIOUR
TasP, PrEP, microbicides, and PEPSE are better understood as
biobehavioral interventions as they are all user dependent,
whether they are pills that need to be taken at a certain frequen-
cy, microbicide gels or rings that need to be inserted and left in
situ for speciﬁed periods, or injectables that require clinic atten-
dance at particular intervals.
Clinical trials of PrEP and ARV-based microbicides have
demonstrated that although adherence to visits was high in
all trials, adherence to product measured objectively through
detection of drug varied considerably [16–18, 20, 46]. In roll-
out programs, uptake of ARV prevention options is more like-
ly to be driven by need than by the beneﬁts inherent in clinical
trial participation [47, 48]. Later in this supplement, Amico
and Stirratt describe the evidence highlighting demographic,
psychological, and socioecological factors related to product
use in placebo-controlled trials to date [49]. Although evi-
dence from FemPrEP and VOICE suggest insufﬁcient levels
of adherence to daily study products, the underlying reasons
for nonadherence are not clear. Until this is understood, we
should not dismiss the potential of daily oral PrEP in similar
populations. Amico and Stirratt highlight the substantial gaps
that remain in our understanding of how and why open-label
PrEP will be adhered to, interrupted, and discontinued. These
gaps hinder our ability to deﬁne clear-cut messages for users
in open-label studies and in real life. Although adherence to
an ARV prevention option will be less obscured by unknown
safety and efﬁcacy of a study product, how will healthcare pro-
viders and users interpret the level of efﬁcacy? And what
impact will the uncertainty around the effect size have on pol-
icy, practice, and adherence?
And what of adherence to TasP in the absence of real-time
feedback of viral load measurements to identify those who
need additional support and to reinforce the value of adher-
ence? The additional beneﬁt of negligible risk of onward trans-
mission may add incentive to receive ART, although,
interestingly, 13% of the HPTN 052 cohort chose to remain
off ART 18 months after unblinding [50].
In addition to noting the extent to which product use in trials
may differ from product adherence in real life, it is likely that
usage patterns will be inﬂuenced by product modality and reg-
imen. CAPRISA 004 evaluated a “before-and-after” dosing of
topical PrEP, whereas FemPrEP and VOICE evaluated daily
dosing strategies of oral and oral–topical PrEP, respectively.
Prior efﬁcacy trials assessed a simple “before-sex” application
of non-ARV vaginal microbicide gel. It is important not to
dismiss the large body of evidence on product use from these
trials because of a lack of biological measures of adherence. Sev-
eral non-ARV microbicide trials used multiple measurement
methods [51] and reported similar disparities between self-
reported point prevalent product use and composite or indirect
measures of product use, as seen in ARV-based trials between
self-reported point prevalent use and drug level counts. In spite
of the limitations of the clinical trial setting, it was possible to
collect data that went beyond acceptability to provide a more
holistic picture of how women incorporated gel into their
lives and partnerships across cultures that will be relevant to
real-life use [52].
ACTUAL RISK AND PERCEIVED RISK
We already know from models of HIV transmission, repeated
cross-sectional studies, and surveillance data collected in the
United Kingdom and the United States that risk behaviors
and markers of risk behavior, such as STIs, continue to in-
crease among MSM [53–58]. This resurgence in STIs com-
pared with the early years of HIV infection predates the
introduction of PrEP. New diagnoses of HIV are also increas-
ing in key populations with stable epidemics. Although use of
new diagnoses to estimate incidence is subject to ascertain-
ment bias due to increased testing, the incidence of HIV in
the placebo group of several HIV prevention trials has been
higher than anticipated [5, 20]. Therefore, it seems likely that
the increase in reported condomless sex is real and prevalent
among HIV-positive and -negative populations. The drivers
are complex and include a change in the sexual environment,
with networks broadening through social networking sites,
changes in sexual risk behaviors [59, 60], and the impact of
modifying a simple “no-sex or condoms-only” instruction to
more nuanced “safer-sex” messages. The role that repeatedly
testing HIV negative while having condomless sex plays in
reinforcing an individual’s perception of their low-risk status
merits evaluation.
Science has facilitated a precise measure of risk of transmis-
sion following sexual exposure based on a composite of the
chance that the person was HIV positive and on the type of
sex. For example, in central London, where prevalence in
MSM is 8.1%, the risk from unprotected receptive anal inter-
course is calculated to be 1 in 1112 with a partner of unknown
status [61]. This creates an impression of low risk, even more so
for insertive anal intercourse where the calculated risk is 1 in
20 408. Are these messages appropriate when we see mean
viral loads of 8 million copies/mL in seroconvertors [62] who
believe themselves to be HIV negative based on their most
recent test?
The longitudinal self-reported risk behavior observed in the
iPrEx cohort [63] suggests that the need for PrEP is more likely
to be periodic than constant. The extent to which PrEP increases
condomless sex with and without an increase in the number of
partners has yet to be characterized. Although PrEP will render
most, if not all, sex acts protected against HIV, it will not
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prevent other STIs and may not prevent HIV transmission
when the viral load is very high, as is the case in seroconversion.
The impact of “risk compensation” on effectiveness and cost-
effectiveness cannot be measured in placebo-controlled trials
when participants know they could be on an inactive drug. Lim-
ited data from open-label extensions of the placebo-controlled
studies in heterosexuals are reassuring [64], but this may not
extrapolate to populations with a greater frequency of partner
change, as is the case with some MSM populations [65].
COST SAVINGS, COST EFFECTIVENESS,
COST BENEFIT
Wilson and Fraser provide a detailed review of the economics of
ARV drugs for prevention in this supplement [66]. They have
highlighted the 4-fold difference between current spending on
AIDS care and treatment and the funds required to treat every-
one living with HIV [37]. There are opportunities for efﬁcien-
cies (task shifting, declining drug costs, cheaper diagnostics),
and it is encouraging to see several low- and middle-income
countries that are now independent of external assistance and
able to consider the cost effectiveness of these new strategies,
with projected cost savings for HIV treatment programs in
the long term. Nonetheless, there remain high-burden countries
that cannot contemplate new options regardless of how good
they appear to be, as they have not yet managed to treat all
those with CD4 <200 cells/mm3. In all settings, the cost beneﬁt
of each strategy has to be considered against the alternatives in
the context of ﬁnite resources within the healthcare sector.
CONCLUSION
The state of the science for biomedical interventions ranges from
weak (for PEPSE), to robust with complex messages (for PrEP),
to robust and clear (for TasP). Postexposure prophylaxis for sex-
ual exposure has been available for some time, and it was possible
to advocate for this with virtually no evidence. For TasP, the US
President’s Emergency Plan for AIDS Relief, WHO, Internation-
al Association of Providers of AIDS Care, International AIDS
Society, US Agency for International Development, and US
Department of Health and Human Services have embraced a
much more aggressive promotion of ART, in part, for the public
health potential. The policy and practice response to PrEP, in
contrast, has been slow and likely reﬂects the more complex mes-
sages that accompany this biomedical intervention, which has
proven to be more behavioral than anticipated. Guidelines and
position statements have been developed; however, uptake, as
measured by prescriptions in the United States, has been poor.
Now is not the time to stand still in admiration of what has
been achieved but rather to double our efforts to answer the ques-
tions that will accelerate implementation of the most appropriate
strategies for each epidemic setting in order to achieve a 50%
reduction in HIV incidence. Failure is not an option.
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